Literature DB >> 17469026

Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy.

Dragomir P Zubac1, Leif Bostad, Charlotta Gestblom, Björn Kihl, Tomas Seidal, Tore Wentzel-Larsen, August M Bakke.   

Abstract

OBJECTIVE: To examine the prognostic significance of performance status, tumour stage, histological subtype, nuclear grade and histological tumour necrosis (HTN) in a population of consecutive patients subjected to radical nephrectomy for renal cell carcinoma (RCC).
MATERIAL AND METHODS: The cohort consisted of 110 males and 86 females with a mean age of 66 years (range 39-88 years). The Eastern Cooperative Oncology Group performance status (ECOG PS) was determined in all cases. The tumours were staged according to the 2002 TNM classification of the American Joint Committee on Cancer. Histological subtype was diagnosed using the Heidelberg classification. Nuclear grading was performed by means of Fuhrman's method. The median follow-up period was 65 months (mean 83 months; range 1-232 months).
RESULTS: Median overall survival (OS) was 65 months and median cancer-specific survival (CSS) was 171 months. CSS was correlated with TNM classification, with the longest survival occurring for stage I and II tumours, shorter survival for stage III tumours and shortest survival for stage IV tumours (p<0.001). A significant difference in CSS was found between T1N0M0 and T2N0M0 tumours (p<0.01). A 15-year CSS of 100% was revealed in patients with tumours </=4 cm in size. There was a significant difference in CSS between low nuclear grade (NG; 1+2) and high NG (3+4) tumours (p<0.001). HTN and ECOG PS were found to be independent prognostic factors (p<0.01).
CONCLUSION: ECOG PS, TNM stage, nuclear grade and tumour necrosis were found to be independent prognostic factors for survival.

Entities:  

Mesh:

Year:  2007        PMID: 17469026     DOI: 10.1080/00365590601016552

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  Pathological implications of areas of lower enhancement on contrast-enhanced computed tomography in renal-cell carcinoma: additional information for selecting candidates for surveillance protocols.

Authors:  Miguel Villalobos-Gollás; Bernardo Aguilar-Davidov; Carolina Culebro-García; Martha O Gómez-Alvarado; Priscila Rojas-Garcia; Raúl Ibarra-Fombona; Norma Uribe-Uribe; Guillermo Feria-Bernal; Ricardo Castillejos-Molina; Mariano Sotomayor; Fernando Gabilondo; Francisco Rodríguez-Covarrubias
Journal:  Int Urol Nephrol       Date:  2012-05-22       Impact factor: 2.370

Review 2.  Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.

Authors:  Hui-Ming Jiang; Jin-Huan Wei; Zhi-Ling Zhang; Yong Fang; Bang-Fen Zhou; Zhen-Hua Chen; Jun Lu; Bing Liao; Fang-Jian Zhou; Jun-Hang Luo; Wei Chen
Journal:  Int Urol Nephrol       Date:  2015-11-20       Impact factor: 2.370

3.  Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.

Authors:  Dragomir P Zubac; Tore Wentzel-Larsen; Tomas Seidal; Leif Bostad
Journal:  BMC Urol       Date:  2010-12-03       Impact factor: 2.264

4.  Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations.

Authors:  Vassilis Samaras; Maria Tsopanomichalou; Angeliki Stamatelli; Christos Arnaoutoglou; Efstathios Samaras; Marianthi Arnaoutoglou; Hercules Poulias; Calypso Barbatis
Journal:  Diagn Pathol       Date:  2009-02-17       Impact factor: 2.644

5.  The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy.

Authors:  Dragomir P Zubac; Leif Bostad; Tomas Seidal; Tore Wentzel-Larsen; Svein A Haukaas
Journal:  BMC Urol       Date:  2008-12-19       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.